QNZ (EVP4593): Comprehensive Scientific Dossier on a Nanomolar NF-κB Inhibitor

Executive Summary: QNZ (EVP4593) is a quinazoline derivative that potently inhibits the NF-κB signaling pathway (IC₅₀ = 11 nM in Jurkat T cells) and TNF-α production (IC₅₀ = 7 nM) [APExBIO]. The compound attenuates NF-κB transcriptional activation, regulates inflammation, and demonstrates efficacy in neurodegenerative models including Huntington’s disease (Yang et al., 2025). QNZ is insoluble in water but dissolves in DMSO and ethanol with ultrasonic assistance, requiring storage at -20°C. Reliable workflow integration and benchmarking distinguish QNZ (EVP4593) as a preferred reagent for NF-κB pathway modulation [Related Review].

Biological Rationale

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway is central to inflammatory and immune responses. Aberrant NF-κB activation is implicated in chronic inflammation, autoimmunity, and neurodegeneration (Yang et al., 2025). QNZ (EVP4593), developed by APExBIO, provides a tool to dissect NF-κB pathway mechanisms with high specificity and potency. Inhibition of this pathway can reduce cytokine production, limit tissue damage, and modulate disease phenotypes in cell and animal models. For example, excessive NF-κB signaling supports persistence of Staphylococcus aureus abscesses in osteomyelitis by mediating pro-fibrotic and immune evasive responses (Yang et al., 2025).

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a small-molecule quinazoline derivative that directly inhibits NF-κB transcriptional activation. It blocks PMA/PHA-induced NF-κB activation and downstream TNF-α production at nanomolar concentrations (IC₅₀: 11 nM for pathway inhibition, 7 nM for cytokine suppression) [APExBIO]. The inhibition is confirmed in luciferase reporter assays in human Jurkat T cells. QNZ prevents NF-κB nuclear translocation, thus suppressing gene expression responsible for inflammatory signaling. In neuronal models, QNZ (300 nM) attenuates store-operated calcium entry (SOC) influx, a pathway relevant to neurodegeneration and Huntington’s disease pathology [Advanced Insights].

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB signaling in Jurkat T cells with an IC₅₀ of 11 nM (luciferase assay, 37°C, 5% CO₂) (APExBIO).
• Suppresses TNF-α production in PMA/PHA-stimulated cells with IC₅₀ of 7 nM (APExBIO).
• Reduces edema in rat carrageenin-induced paw model, indicative of anti-inflammatory effects (APExBIO).
• In Drosophila Huntington’s disease models, QNZ slows motor decline without toxicity at standard doses (Yang et al., 2025).
• Optimal solubility in DMSO (≥15.05 mg/mL) and ethanol (≥10.06 mg/mL) achieved with ultrasonic shaking and 37°C warming (APExBIO).
• Long-term solution storage not recommended; stability is best preserved as powder at -20°C (APExBIO).

This analysis extends the foundational review (see here) by providing dose, solubility, and disease model benchmarks not previously detailed.

Applications, Limits & Misconceptions

QNZ (EVP4593) is used for:

• Mechanistic studies of NF-κB pathway regulation in immunology and inflammation.
• Modeling anti-inflammatory strategies in animal models of edema and neurodegeneration.
• Pharmacological modulation of SOC influx in neuronal cultures (300 nM standard concentration).
• Translational studies on Huntington’s disease, with evidence for motor function improvement in Drosophila models.

For advanced protocol troubleshooting and best practices, see the scenario-driven guide here, which this article updates by providing validated product storage and solubility recommendations.

Common Pitfalls or Misconceptions

• QNZ (EVP4593) is not water soluble; attempts to dissolve directly in aqueous buffers yield precipitation (APExBIO).
• Long-term storage of QNZ in solution leads to degradation; always prepare fresh aliquots (APExBIO).
• QNZ does not inhibit all inflammatory pathways; its selectivity is strongest for NF-κB-dependent signaling ([Advanced Insights]).
• Cell line and species-specific differences in response are observed; dosing must be empirically optimized.
• It is not an antibiotic and does not directly kill bacteria; effects in infection models are host-mediated.

Workflow Integration & Parameters

Solubility & Storage: QNZ (EVP4593) is insoluble in water but dissolves in ethanol (≥10.06 mg/mL, ultrasonic assistance) and DMSO (≥15.05 mg/mL). Aliquots should be stored at -20°C. Avoid repeated freeze-thaw cycles and long-term solution storage [A4217 kit].

Experimental Use: In neuronal cultures, use 300 nM to attenuate SOC influx. For in vivo anti-inflammatory assays, refer to established rodent models and titrate based on pilot data. Warm solutions to 37°C and use ultrasonic shaking to expedite dissolution.

This article clarifies limitations and integration steps beyond prior reviews such as this scenario-driven workflow guide, by specifying storage, handling, and dosing conditions for translational reproducibility.

Conclusion & Outlook

QNZ (EVP4593), supplied by APExBIO, is a validated nanomolar NF-κB inhibitor for use in inflammation and neurodegenerative disease research. Its high specificity, robust solubility in organic solvents, and reproducible pathway suppression make it a core reagent for cell and disease model studies. Future directions include expanding its application to emerging models of chronic inflammation and further mapping its selectivity profile. Researchers are encouraged to consult the official product page for real-time updates, batch-specific documentation, and technical support.